Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
The combination is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy
Findings from the HERB study
Findings from the LITESPARK-005 study
Evidence for efficacy is based on the results from the INDIGO study
It is intended for the treatment of CLDN18.2-positive gastric or gastro-oesophageal junction adenocarcinoma
Findings from the TURBO-NSCLC study
Findings from the CUPISCO study
The combination is indicated for the treatment of adult patients with advanced NSCLC with a BRAF V600E mutation
Findings from the COOG2 study
It is intended for the first-line treatment of patients with nasopharyngeal carcinoma and oesophageal squamous cell carcinoma
Results from the AtezoTRIBE study
Findings from the long-term follow-up analysis of the PRODIGY study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
